Abstract
Neuropeptide Y (NPY), a potent orexigen peptide widely produced and distributed in arcuate neurons in the hypothalamus, is a promising candidate for the control of appetitive ingestive behavior. In mammals, the signaling is mediated via at least five different cell surface receptors, denoted as Y1, Y2, Y4, Y5 and Y6. Obesity is an important public health problem in the world, particularly in developed societies, and has taken on pandemic proportions. The therapeutics of obesity, including appetite suppressants, has increased 453% over the past decade, although issues concerning safety, efficacy, and little knowledge of the pharmacological activity result in the still modest effects of the anti-obesity drugs presently used. Ligands for Y receptors may be of benefit for the treatment of obesity, and recent findings have indicated a promising role of Y2 and Y4 in protecting against diet-induced obesity. This review highlights the supporting evidence therapeutic potential of Y2 and Y4 receptors antagonists as additional intervention to treat human obesity.
Keywords: Appetite Regulation, Body Weight, Food Intake, Neuropeptide Y, Neuropeptide Y Receptors, Obesity
Current Topics in Medicinal Chemistry
Title: NPY Y2 and Y4 Receptors Selective Ligands: Promising Anti-Obesity Drugs?
Volume: 7 Issue: 17
Author(s): M. M. Kamiji and A. Inui
Affiliation:
Keywords: Appetite Regulation, Body Weight, Food Intake, Neuropeptide Y, Neuropeptide Y Receptors, Obesity
Abstract: Neuropeptide Y (NPY), a potent orexigen peptide widely produced and distributed in arcuate neurons in the hypothalamus, is a promising candidate for the control of appetitive ingestive behavior. In mammals, the signaling is mediated via at least five different cell surface receptors, denoted as Y1, Y2, Y4, Y5 and Y6. Obesity is an important public health problem in the world, particularly in developed societies, and has taken on pandemic proportions. The therapeutics of obesity, including appetite suppressants, has increased 453% over the past decade, although issues concerning safety, efficacy, and little knowledge of the pharmacological activity result in the still modest effects of the anti-obesity drugs presently used. Ligands for Y receptors may be of benefit for the treatment of obesity, and recent findings have indicated a promising role of Y2 and Y4 in protecting against diet-induced obesity. This review highlights the supporting evidence therapeutic potential of Y2 and Y4 receptors antagonists as additional intervention to treat human obesity.
Export Options
About this article
Cite this article as:
Kamiji M. M. and Inui A., NPY Y2 and Y4 Receptors Selective Ligands: Promising Anti-Obesity Drugs?, Current Topics in Medicinal Chemistry 2007; 7 (17) . https://dx.doi.org/10.2174/156802607782340957
DOI https://dx.doi.org/10.2174/156802607782340957 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Small Peptide and Protein-based Molecular Probes for Imaging Neurological Diseases
Current Protein & Peptide Science Antibodies for Therapeutic Uses and the Evolution of Biotechniques
Current Medicinal Chemistry Induced Pluripotent Stem Cell-Based Studies of Parkinson's Disease: Challenges and Promises
CNS & Neurological Disorders - Drug Targets Use of STAT1 Inhibitors in the Treatment of Brain I/R Injury and Neurodegenerative Diseases
Central Nervous System Agents in Medicinal Chemistry Microglia Activation Precedes the Anti-Opioid BDNF and NMDA Receptor Mechanisms Underlying Morphine Analgesic Tolerance
Current Pharmaceutical Design Expanding Spectrum of Sodium Potassium Chloride Co-transporters in the Pathophysiology of Diseases
Current Neuropharmacology Destination Penis? Gene Therapy as a Possible Treatment for Erectile Dysfunction
Current Gene Therapy Exercise as Treatment for Neuropathy in the Setting of Diabetes and Prediabetic Metabolic Syndrome: A Review of Animal Models and Human Trials
Current Diabetes Reviews Cell Culture in Microfluidic Systems
Micro and Nanosystems Hydroxysafflor Yellow A Attenuates Renal Ischemia- Reperfusion Injury in a Rat Model
Letters in Drug Design & Discovery Clinical Uses of Melatonin in Neurological Diseases and Mental and Behavioural Disorders
Current Medicinal Chemistry EDITOR’S PERSPECTIVE [The Challenges for Drug Development: Cytokines, Genes, and Stem Cells]
Current Neurovascular Research Applications of Computed Tomography, Magnetic Resonance Imaging and Magnetic Resonance Spectroscopy for Planning External Beam Radiotherapy
Current Medical Imaging Advances Towards The Discovery of GPR55 Ligands
Current Medicinal Chemistry Recent Advances in Delivery Through the Blood-Brain Barrier
Current Topics in Medicinal Chemistry Iron Oxide Nanoparticles: An Insight into their Biomedical Applications
Current Medicinal Chemistry Editorial [ Medicines Da Vinci Code: Deciphering the Intricate Origins of Clinical Neurovascular Pathology K. Maiese ]
Current Neurovascular Research Neurological Substrate of Central Auditory Processing Deficits in Children
Current Pediatric Reviews Targeting Heme Oxygenase-1 in Vascular Disease
Current Drug Targets Monoamine Oxidases: The Biochemistry of the Proteins As Targets in Medicinal Chemistry and Drug Discovery
Current Topics in Medicinal Chemistry